Mar/15/2008 07:51
John C. Lechleiter,
an Eli Lilly official who is about to become the
company’s top executive, wrote an e-mail message in
2003 that appears
to have
encouraged Lilly to promote its schizophrenia
medicine Zyprexa for a use not approved by federal
drug regulators. This in common terms is known as
"open mouth A and insert foot "B" and shows just high
up the chain managers at Lilly went to expand sales
of Zyprexa. Read
More...
Mar/10/2008 06:27
From today's New
York TImes comes an interesting editorial on Avastin:
The Food and Drug Administration’s recent approval of
Avastin, a hugely expensive drug, to treat advanced
breast cancer has raised perplexing issues for women,
their doctors and the entire health care
system. Read
More...
Mar/08/2008 07:20
The trial between
Lilly and the state of Alaska over Zyprexa is
interesting to watch unfold. First you have a legal
team from Alaska that leaked pretrial discovery
information to the media (The New York Times which is
also covering the trial in depth), a state that
continues to use Zyprexa and has refused to settle
with Lilly even though Lily has paid out over a
billion dollars. So what is the purpose of this
trial? To call Lilly a liar and prove that they
withheld data to protect sales at the expense of
patients health? Or for an over aggressive attorney
to make a name for himself? Read
More...
